UNIQURE
uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. Our first product, Glybera, was approved by the European Commi... ssion in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease. We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations.
UNIQURE
Industry:
Biotechnology Genetics Health Care Medical
Founded:
2012-11-01
Address:
Amsterdam, Noord-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.uniqure.com
Total Employee:
51+
Status:
Active
Contact:
+31 20 566 7394
Email Addresses:
[email protected]
Total Funding:
167 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics Apache Microsoft Exchange Online
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Aprea
Aprea focuses on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53.
CasZyme
CasZyme is a biotech firm that is involved in research & development of cas proteins and CRISPR based molecular tools.
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
LYSOGENE
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders.
Medicinal Genomics
Medicinal Genomics is pioneering the genomics of medical cannabis and hemp.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-06-23 | Corlieve Therapeutics | Corlieve Therapeutics acquired by UniQure | 46.3 M EUR |
| 2014-08-12 | InoCard | InoCard acquired by UniQure | N/A |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - UniQure
Forbion Capital Partners
Forbion Capital Partners investment in Private Equity Round - UniQure
Chiesi Pharmaceuticals
Chiesi Pharmaceuticals investment in Private Equity Round - UniQure
Coller Capital
Coller Capital investment in Private Equity Round - UniQure
Official Site Inspections
http://www.uniqure.com Semrush global rank: 1.54 M Semrush visits lastest month: 16.96 K
- Host name: 20.49.104.15
- IP address: 20.49.104.15
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
